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ABSTRACT
Objectives: Genetic mutations in breast cancer susceptibility genes
BRCA1/2 are associated with an increased risk of breast/ovarian cancers.
Cost-effective preventive measures are available for women who test posi-
tive. The objective of this study was to determine at what risk of mutation
it is cost-effective to test women for BRCA1/2 mutations.
Methods: A semi-Markov model accrued costs and quality-adjusted life
years (QALYs) annually from the societal perspective. The estimates of
health-care costs, life expectancy, likelihood of obtaining a mastectomy or
oophorectomy, and patient preferences for treatment and certainty about
their BRCA1/2 status were based on the literature.
Results: At a 10% probability of mutation (the current guideline), the test
strategy generated 22.9 QALYs over the lifetime and cost $118k, while the
no-test strategy generated 22.7 QALYs and cost $117k. The incremental
cost-effectiveness ratio of the test strategy was $9k and the differences
between costs and effects were not substantial. The test strategy remained
cost-effective to a probability of mutation of 0%, as long as utility gained
from a negative test result was 0.006 or greater. These results were sensi-
tive to the frequency of inconclusive test results and utility gain from a
negative test result.
Conclusions: The costs and effectiveness of both the test and no-test
strategies are very similar even when there is a small probability of muta-
tion. Current guidelines, which can be used by insurance companies to
refuse coverage, could deny some women a cost-effective approach.
Further research to decrease the frequency of inconclusive results could
improve the cost-effectiveness of this test.
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Mutation in breast cancer susceptibility genes (BRCA1 and
BRCA2) is associated with an increased risk of breast and
ovarian cancers, accounting for approximately 5% to 10% of
breast cancers and 10% of ovarian cancers [1]. It is estimated
that 30% of families with a strong history of breast and ovarian
cancers carry one of these mutations [2], but only one in 300 to
500 people in the general population carry the genes [3]. In the
United States, Myriad Genetic Laboratories is the sole commer-
cial laboratory for BRCA1/2 testing.
There are several possible interventions to help prevent breast
and ovarian cancer. Prophylactic surgeries to remove breasts
(mastectomy) and/or ovaries (oophorectomy) can signiﬁcantly
decrease the rates of cancer [4]. Prophylactic surgery can be
performed in the absence of a positive BRCA test, but is rare in
women who have not either been tested or had previous breast or
ovarian cancer [5]. Chemoprevention has also been shown to
reduce the risk of cancers [4]. Each of these strategies, however,
could have dramatic effects on quality of life because of associ-
ated heath risks and side effects. For instance, mastectomy is a
major surgery that leaves visible change to the body, which some
women may ﬁnd unacceptable. Although reconstruction is pos-
sible, it carries its own costs, risks, and discomfort. Oophorec-
tomy removes child-bearing opportunities without further
medical intervention and may also induce unpleasant side effects
associated with menopause.
Screening, such as mammography, is widely used for the early
detection of cancers. It is recommended that high-risk women
begin mammography as early as their 20s to 30s in combination
with yearly clinical breast exams and often additional imaging
modalities.
Several studies have shown that oophorectomy is the optimal
intervention strategy for BRCA mutation carriers when patient
preferences are included, but the combination of mastectomy and
oophorectomy is optimal if the sole consideration is life expect-
ancy [4,6]. The strategies compared by Anderson et al. were:
chemoprevention, oral contraceptives, oophorectomy, mastec-
tomy, both surgeries, and surveillance [4]. Van Roosmalen et al.
considered: both surgeries, mastectomy and ovarian cancer sur-
veillance, oophorectomy and breast cancer surveillance, and
screening for both diseases [6].
Current guidelines recommend genetic testing for women
with estimated probabilities of having mutations in BRCA1 or 2
genes of 10% or greater [7]. A woman of Ashkenazi Jewish
ancestry meets this criterion if she has one relative (ﬁrst or second
degree) with breast cancer before age 50 or ovarian cancer at any
age; a non-Ashkenazi Jewish woman needs a family history (ﬁrst
or second degree) of both breast cancer before 50 and ovarian
cancer at any age [8]. The insurance coverage for BRCA1/2
testing varies by the source of coverage. Currently, Medicaid
coverage of BRCA1/2 testing is determined by each individual
state [9]. Commercial insurance plans, Medicare, and some
Medicaid plans use a basic family history algorithm to determine
individual coverage [10–17].
These algorithms, which can also be used to estimate the
probability of mutation, consider the prevalence of breast and
ovarian cancers in ﬁrst-degree relatives (mother or sisters) and
second-degree relatives (grandmothers, aunts, or half-sisters)
and whether any breast cancers were pre- or postmenopausal [2].
A sample of seven commercial plans with criteria available on the
Internet revealed that the cutoffs are generally equivalent to a
probability of 8% to 10% based on data from Myriad’s website
[8,11–17], although some plans have more stringent guidelines
than others. Several plans allow testing for a woman with three
or more affected family members, regardless of age or type of
cancer [11,16], although several others require that at least one
relative to be diagnosed with breast cancer before age 50 or have
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ovarian cancer [12–14]. Most plans require less family history
for those of Ashkenazi Jewish descent [11–17].
The current BRCA1/2 testing guideline was established
before commercial testing for BRCA2 was available, and did not
incorporate a cost-effectiveness (CE) analysis [7]. CE evaluation
can provide important information about the beneﬁt of testing
for the gene compared to its costs. The only study we found that
considered the CE of testing for BRCA was published in 1999. It
was focused on individuals of Ashkenazi Jewish descent (a high-
risk population with 2.5% probability of mutation) and found
that testing was cost-effective only when all women who tested
positive underwent prophylactic surgery [18]. Our study aims to
identify the threshold probability of BRCA mutation above
which it would be cost-effective to test women for BRCA1/2 gene
mutation. This information could be used by health plan admin-
istrators to make coverage decisions.
Methods
Model Description
A cost-utility model was created to compare costs and utilities
associated with the probability of BRCA1/2 mutation in women
without cancer. The target population was 35-year-old women
with an associated family risk of breast and/or ovarian cancer
and any other 35-year-old women who are concerned about
having the mutation. The age of 35 was chosen because this is an
appropriate age to consider testing and prophylactic surgery. Few
breast or ovarian cancers are diagnosed before age 40 and are
rare before 30 [19]. Although some younger women may choose
to be tested [20], few women are likely to choose surgery before
their mid-30s [20–22], because of the impact on child-bearing
potential.
We deﬁned the intervention (“test strategy”) as genetic
testing for BRCA mutation at age 35, followed by the possi-
bility of preventive surgery if a mutation was found. Women
entering the model had an estimated pretest probability of
having a genetic mutation of 10% or higher in the base case.
This implies some family history, but not necessarily a known
mutation in the family. The “test strategy” was compared to
the “no-test strategy,” in which there was no genetic testing
and no prophylactic surgery, but did include ongoing screening
according to recommendations.
Oophorectomy or mastectomy were utilized at the rate
expected for BRCA positive women, which increased over time
as women aged, presumably completed childbearing, and
approached natural menopause. Neither surgery was considered
a possibility for those who received a negative test result or
were not tested, because of low rates of prophylactic surgery
without a positive test result [5,23]. Because a woman’s genetic
status does not change over time, and the test has high sensi-
tivity, the test was only conducted once. Chemoprevention was
not considered here, because of the low rates of use among
those with known mutation, but without previous cancer
[5,24]. Screening continued for all women, regardless of muta-
tion status.
A semi-Markov model was created in TreeAge Pro 2007
(TreeAge Software, Inc., Williamstown, MA) The initial decision
was between receiving the genetic test at age 35 (test strategy)
and not receiving the test (no-test strategy). The sensitivity and
speciﬁcity of the test were modeled by including probabilities of
false-negative and false-positive results. The possibility of surgery
was only considered if a genetic mutation was found. A woman
could choose surgery in the year she received a positive test result
or she could postpone surgery. In each cycle (1 year), a woman
with a positive test result, no prior surgery, and no cancer could
choose surgery, which would then alter her future utilities and
probabilities of cancer. If oophorectomy was performed after age
50, there was a reduction in the risk of ovarian cancer only;
breast cancer risk remained as if there were no surgery. The
possibility of a woman having both surgeries (oophorectomy and
mastectomy) was not included in the model because of the low
rate (2%) of women choosing this option [5] and a lack of data
regarding the risk reduction possible from this combination. The
model estimated a maximum of 70-year-long cycles.
According to our model, a woman could pass through up to
six of the nine health states, as shown in Figure 1: well, BRCA
status unknown; well with mutation; well without mutation;
mastectomy (only allowed if mutation was found); oophorec-
tomy (only allowed if mutation was found); breast cancer;
ovarian cancer; both breast and ovarian cancers; and death.
Death was the absorbing state and a woman could remain in any
of the other states for multiple cycles. The estimated incidences of
breast and ovarian cancers were modeled based on estimates
found in the literature (Table 1) [25,26]. In this model, it was
possible for a woman to develop ovarian cancer after breast
cancer. Breast cancer after ovarian was not included, because the
incidence is expected to be low given the relatively low probabil-
ity of ovarian cancer [25,26] and its high mortality rate [27].
After cancer diagnosis, utility and health-care costs were affected
by cancer for the remainder of her life. The year in which cancer
was diagnosed had lowered utility and increased costs because of
the testing, procedures, and resulting stress. In subsequent years,
the utilities accrued annually were less than 1, but greater than
in the year of cancer diagnosis and treatment. Costs were higher
than “well,” but lower than in the year of diagnosis, because of
possible continued medical care and side effects of treatment. The
ﬁnal year of life had increased costs because of the ﬁnal stages of
Table 1 Breast and ovarian cancer risks by decade
Variable Estimate
Cumulative breast cancer risk: general population by
decade [26]
30 [25] 0
40 0.002
50 0.012
60 0.022
70 0.045
80 0.068
Breast cancer risk: BRCA + by decade [26]
30 [25] 0.020
40 0.104
50 0.423
60 0.628
70 0.686
80 0.735
Ovarian cancer risk: general population by decade [26]
30 [25] 0
40 0.001
50 0.003
60 0.005
70 0.011
80 0.018
Ovarian cancer risk: BRCA + by decade [26]
30 [25] 0
40 0.004
50 0.094
60 0.146
70 0.215
80 0.278
Annual rates used in the model were calculated based on these cumulative rates assuming a
linear increase in risk throughout each decade. For sensitivity analysis, cancer risk was varied
between zero to twice as likely as the base estimate using a uniform distribution.
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the illness, which were dependent on the previous health state
(breast cancer, ovarian cancer, or well).
For this study, we adopted the societal perspective, with a
boundary at the patient-speciﬁc costs and beneﬁts only. Health-
related quality of life for the patient was included, but the effects
of genetic status on other family members were not. This was
assumed to be small in comparison to the quality of life impact
the test results, surgery, and cancer has on the patient herself.
Because an earlier study demonstrated that overall breast cancer
does not have a signiﬁcant affect on women’s wages [28], we did
not consider productivity losses.
The probability of an otherwise healthy woman dying was
age-speciﬁc, based on the National Vital Statistics Report (range:
0.00096–0.35) [29]. After cancer was diagnosed, mortality was
increased for 20 years for breast cancer and 10 years for ovarian
cancer [30] and then reverted to the noncancer rates. For breast
cancer, the annual mortality rate was 0.0229 [31] (range for
sensitivity analysis: 0.01–0.05) and for ovarian it was 0.160 [31]
(range: 0.08–0.32).
Although previous data suggest that the sensitivity and speci-
ﬁcity of commercial genetic testing exceed 99% [3], more recent
studies suggest that the sensitivity of the test for detecting all
genetic mutations increasing the risk for breast and ovarian
cancers may be signiﬁcantly lower [32]. Therefore, sensitivity
analysis on the sensitivity of the test was investigated (range:
0.5–1.0). A range of 0.95 to 1.0 was used for speciﬁcity.
A review article by Wainberg and Huste [22] provided a range
of probabilities for women with a known BRCA1/2 mutation
obtaining prophylactic surgery (Table 2). Because some women
may not have completed childbearing by age 35 or may have
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Figure 1 The conceptual model consists of nine
states as shown. The dotted line shows that test
results are only received in the ﬁrst year. Prophy-
lactic surgery is only allowed for those receiving
positive test results (true positives and false
positives).
Table 2 Prophylactic surgeries: rates of use and risk reduction
Variable Estimate Range Standard error
Rates of use
Mastectomy at 35 years, BRCA1/2 mutation [22] 0.15 0.03–0.54 0.13*
Maximum likelihood of mastectomy [22] 0.50 0.20–0.80 0.15*
Age at maximum mastectomy likelihood 60 50–70 5*,†
Oophorectomy at 35 years, BRCA1/2 mutation [22] 0.25 0.13–0.78 0.17*
Maximum likelihood of oophorectomy [22] 0.64 0.50–0.80 0.08*
Age at maximum oophorectomy likelihood 60 50–70 5*,†
Decrease in risk because of mastectomy
Breast cancer [4] 0.90 0.80–0.99 0.05
Ovarian cancer [4] 0 0 0
Decrease in risk because of oophorectomy
Breast cancer (if surgery before age 50) [4] 0.45 0.25–0.65 0.10
Ovarian cancer [4] 0.96 0.90–0.99 0.03
*Estimated from ranges, based on Briggs Equation 1 [54].
†Gamma distribution used for sensitivity analysis.
For probabilistic sensitivity analysis, beta distributions were used for the values in this table, except as noted.
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other reasons to postpone prophylactic surgery, the rates of each
increased over time, until the woman reached age 60.
Utility Data
Patient utilities were estimated based on existing literature esti-
mates and the authors’ assumptions, as shown in Table 3. The
utilities for most breast- and ovarian-cancer-related health states
were estimated by Grann et al. using the time-trade-off technique
[33,34]. The estimates used were from the reference group of
women, ages 33 to 50. The utility for breast cancer was estimated
based on a group of four studies [35–38]. The results were similar
for each, although no single study was ideal for this purpose,
because of the various subpopulations used, such as advanced
stages of cancer or age. The disutilities of cancer diagnosis were
from the CEARegistry [39]. The boundary of the study was set on
the patient herself and, hence, no utility of any other party (i.e.,
patient’s mother, daughter, or other relatives) was considered.
Using the time-trade-off technique, utilities were estimated by
trading off years of life and reﬂect the indirect beneﬁts that could
be gained during these years [33]. For both breast and ovarian
cancer, there was a greater decrease in utility in the year of
diagnosis. The woman remained in the breast and/or ovarian state
for the remainder of her life at a reduced utility.
The utility estimate for carrying the mutation was taken from
Cappelli [40]. No estimates were found in the literature for the
utility of not knowing one’s genetic status. Nevertheless, an
increase in utility is expected if a negative test result is obtained,
because the target population has reason to be concerned about
a mutation. Lerman et al. found that a negative test result
improved psychosocial functioning, and that positive results
did not increase depressive or functional impairment [41]. The
beneﬁt of receiving a negative result was included in the model as
a one-time increase of 0.01 for the ﬁrst cycle in those who are
tested and learn they do not have the mutation. Romano et al.
estimated a utility of 0.9998, based on a willingness-to-pay study,
for not receiving an ultrasound screening for birth defects during
a low-risk pregnancy [42]. This very slight decrease from the
ideal utility of 1.0 represents the loss in utility from a concern
about defects. Because genetic defects in low-risk pregnancies are
less common than the genetic mutations in this target population,
it was reasonable to choose a slightly larger utility change for a
BRCA1/2 screening result. The impact of this assumption was
tested through sensitivity analysis.
We assumed that utilities for knowledge of mutation, mas-
tectomy, and oophorectomy would increase after the year of
diagnosis, in part because of adaptation. The literature suggests
that women with a positive test result are not signiﬁcantly psy-
chologically different than other women 5 years after the test
result [43]. Therefore, we modeled the utility increase linearly
from the initially decreased value to the age-speciﬁc value over 5
years and the woman remained at a normal age-speciﬁc quality
of life in subsequent years. As a woman ages, the effects of
prophylactic surgery on utility can be expected to decrease. For
oophorectomy, most of the negative impacts are related to meno-
pause, so this difference in utility was assumed to reduce to zero
by age 60. For mastectomy, the side effects also reduce over time
and a study of women 2 to 23 years after the procedure showed
no decrease in utility [44]. Therefore, it was assumed that the loss
of utility because of mastectomy would also reduce to zero by age
60. These utility changes were modeled as linearly increasing
from the time of surgery until the given age was reached. The
inﬂuences of changes in utilities over time were explored through
sensitivity analysis and the linear assumption was tested by mod-
eling the increase as an exponential function asymptotically
approaching the age-speciﬁc value.
Cost Data
Health-care costs were estimated by using reimbursement rates.
Cost data were primarily obtained from Anderson et al. [4],
where the costs were summarized from several sources and
adjusted to 2006 dollars (Table 4), using the medical care com-
ponent of the Consumer Price Index [45]. Anderson’s data came
from: Kaiser Permanente for cancer contributable costs, which
includes all insured costs up to 15 years post-diagnosis [46];
Riley et al. [47] and Lubitz and Riley’s [48] Medicare data for
end-of-life costs for cancer and noncancer patients; and the 2004
Table 3 Base-case utilities and ranges
Variable Estimate Range Standard error
Well state
Age-speciﬁc utility, at age 35 [38] 0.92 0.8–1 0.002
Annual decrease in utility because of age [38] 0.00029 0–0.001 0.000006
Increase in utility with test result: mutation not found 0.01 0–0.1 n/a*
Test result: mutation found [40] 0.75 0–1 0.25
Time to return to normal age-speciﬁc utility after mutation found (years) 5 1–20 4.8†,‡
Breast cancer state
Decrease in utility in year of diagnosis [39] 0.20 0–1 0.03§
Initial utility of breast cancer [35–38] 0.75 0–1 0.20
Increased utility in years after breast cancer diagnosis [35] 0.89 0.5–1 0.13
Years to increased utility [35] 2 1–5 1.0†,‡
Ovarian cancer state
Decrease in utility in year of diagnosis [39] 0.29 0–1 0.12§
Utility of being in ovarian cancer health state [34] 0.58 0–1 0.36
Prophylactic oophorectomy
Utility in ﬁrst year postoophorectomy [34] 0.68 0.5–1 0.36
Age postoophorectomy to return to normal age-speciﬁc utility 60 45–75 7.7
Prophylactic mastectomy
Utility in ﬁrst year postmastectomy [34] 0.82 0.5–1 0.39
Age postmastectomy to return to normal age-speciﬁc utility 60 55–85 7.7
Utility discount rate [33] 3% 0% to 7% n/a*
*Uniform distribution used for sensitivity analysis.
†Estimated from ranges, based on Briggs Equation 1 [54].
‡Gamma distribution used for sensitivity analysis.
§Where standard errors were not available from the literature, a coefﬁcient of variation of 0.4 was used to estimate the standard error [54].
For probabilistic sensitivity analysis, beta distributions were used for the values in this table, except as noted.
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Drug Topics Red Book for drug costs [49]. Costs for genetic
testing and counseling are taken from Lawrence et al. [50]. Out-
of-pocket costs for cancer treatments, terminal care, and prophy-
lactic surgeries are included. These are based on breast cancer
treatment costs from Arozullah et al. [51]. Four months of treat-
ment are assumed (range: 1–8 for sensitivity analysis) [52] and
out-of-pocket costs for other conditions were estimated based on
the same ratio of out-of-pocket costs to medical costs as initial
breast cancer treatment.
The model estimated the total costs over the woman’s life-
time, which was assumed to be, at most, 70 years after testing.
The model ended at death or when the woman reached 105 years
old. This age was chosen to ensure that the full lifetime of all
individuals in the model was captured. Quality-adjusted life
years (QALYs) and costs were both discounted at a rate of 3% at
baseline and varied between 0% and 7% for sensitivity analysis
[33].
Currently, results of genetic testing can be interpreted as
positive, negative, or inconclusive. Results are inconclusive when
a mutation of unknown clinical signiﬁcance is found. When an
inconclusive result is received, treatment decisions are based on
prior family history and other risk factors. Until the clinical
relevance of each possible mutation is established, it is not pos-
sible to know the likelihood of cancer in women with these
results. Because of the uncertainty surrounding this issue, our
base case did not include the possibility of inconclusive results.
Nevertheless, we explored the effects of inconclusive results by
evaluating two extreme scenarios: one assuming all inconclusive
results were false positives (i.e., treated as mutation, but no
increased risk of developing cancer) and the other assuming all
inconclusive results were false negatives (i.e., treated as no muta-
tion, but with elevated cancer risk). The percent of test results
that were expected to be inconclusive (13%) was based on data
from Myriad Genetic Laboratories [53].
Analysis
Based on the modeling predictions, we calculated the incremental
cost-effectiveness ratio (ICER) of the test strategy compared to
the no-test strategy. Sensitivity analysis was performed to deter-
mine the threshold probability of mutation that makes genetic
testing cost-effective. To explore sources of uncertainty and the
effects of assumptions and parameter variation on results, one-
way sensitivity analysis was used to identify the most sensitive
parameters. This analysis varied all of the input values across the
range of potential values shown in Tables 1–4, while holding the
other values constant at their base value. The ranges of CE ratios
were recorded for each parameter.
Finally, we performed probabilistic sensitivity analysis using
Monte Carlo simulation with 10,000 iterations to determine the
uncertainty around the ICER. Beta distributions were used for
utilities and probabilities to restrict the possible values to be
between 0 and 1 [54]. Although it is possible for utilities to be
below 0, the lowest utility parameter used here was 0.58 and we
did not expect any of the values to approach 0. Gamma distri-
butions were used for modeling costs and for the number of years
over which a utility value increased, such as following cancer
diagnosis. The gamma distribution restricts values to be above 0,
but is otherwise similar to a normal distribution. For beta and
gamma distributions, parameters were estimated by TreeAge
software based on means and standard errors (Tables 2–4).
Results
Base-Case
The test strategy was estimated to cost $118k and result in 22.9
QALYs. The no-test strategy was estimated to cost $117k and
result in 22.7 QALYs. At the current guideline level of 10%
probability of mutation, the testing strategy was not substantially
different than the no-test strategy and the ICER was $9k. Table 5
shows other outputs of the model for each arm. For the test
strategy, those with the mutation accumulate 20.5 QALYs and
those without the mutation accumulate 23.1 QALYs.
Sensitivity Analysis
The test strategy was cost-effective at a pretest probability of
mutation of 0%, as long as the utility gain from a negative test
Table 4 Costs in 2006 dollars
Variable Estimate Range Standard error
Genetic testing [50] $2,542 1,301–5,421 1,017
Health-care costs when well [4] $3,904 1,951–7,806 1,561*
Terminal care without cancer [4] $31,210 21,683–37,946 12,484*
Out-of-pocket costs for terminal care without cancer $7,322 3,686–14,094 9,947
Breast-related
Mastectomy [4] $12,254 5,963–23,852 4,902*
Out-of-pocket costs for mastectomy [51] $2,875 1,409–5,421 3,905
Newly diagnosed breast cancer [4,46] $28,635 14,094–56,377 228
Out-of-pocket costs for ﬁrst year with breast cancer [51] $6,718 3,252–13,010 9,126
Ongoing breast cancer (annual) [4,46] $7,355 3,795–13,010 121
Out-of-pocket costs for ongoing breast cancer $1,726 867–3,252 2,344
Terminal care with breast cancer [4,46] $42,209 32,525–48,787 1,474
Out-of-pocket costs for terminal breast cancer $9,903 4,879–19,515 13,452
Ovary-related
Oophorectomy [4] $5,011 2,494–9,757 2,005*
Out-of-pocket cost for oophorectomy $1,176 542–2,168 1,597
Newly diagnosed ovarian cancer [4,46] $59,979 29,272–119,258 2,231
Out-of-pocket costs for ﬁrst year with ovarian cancer $13,436 6,505–27,104 18,252
Ongoing ovarian cancer [4,46] $10,901 5,421–21,683 840
Out-of-pocket costs for ongoing ovarian cancer $2,557 1,301–5,421 3,474
Terminal care from ovarian cancer [4,46] $42,004 32,525–48,787 3,004
Out-of-pocket costs for terminal ovarian cancer $9,854 4,879–19,515 13,387
Cost discount rate [33] 3% 0% to 7% n/a†
*Where standard errors were not available from the literature, a coefﬁcient of variation of 0.4 was used to estimate the standard error [54].
†Uniform distribution used for sensitivity analysis.
Gamma distributions were used in sensitivity analysis for all costs [54].
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result was at least 0.006 (Table 6). This table illustrates that
increasing the probability of mutation decreased the CE of the
test strategy until the utility increase from a negative test result
was 0.010 or greater.
The model was most sensitive to utility after BRCA mutation
diagnosis in the ﬁrst year, utility during the ﬁrst year after mas-
tectomy, utility gain from a negative test result, and the discount
rate. The ICER was fairly stable when the utility after BRCA
mutation diagnosis was between 0.1 and 0.98 (below $50k/
QALY; Fig. 2). As the utility of the ﬁrst year after mastectomy
decreased, the test strategy became less cost-effective, but the
ICER remained lower than $50k/QALY until the utility reached
0.48. Table 6 shows that the no-test strategy dominated when the
utility from a negative test result was below 0.006. As the dis-
count rate increased, the test strategy became less cost-effective,
but the ICER remained lower than $50k/QALY until the dis-
count rate reached 8.5%.The ICER remained below $50k/QALY
for all other parameters, including those estimates discussed
earlier as being less well-established and therefore requiring close
attention. Using an exponential function (instead of the base case
linear function) to return the utilities of those with positive test
results, mastectomy, or oophorectomy to the age-speciﬁc quality
of life decreased the ICER to $7k/QALY; those with the mutation
accumulated 20.859 QALYs in the test strategy and 20.851
QALYs in the no-test strategy, although those without the muta-
tion accumulated 23.1 QALYs in the test strategy and 22.9
QALYs in the no-test strategy.
When inconclusive results were included in the model as the
two extreme cases (all false positives or all false negatives), only
the outcomes in the test strategy changed and the no-test strategy
dominated. For the false positive case, test strategy cost was
slightly less ($118k vs. $117) and resulted in fewer QALYs (22.7
vs. 22.9). When inconclusive results were treated as false nega-
tives, the cost for the test strategy was higher ($123k) and there
was a greater decrease in beneﬁts (22.6 QALYs).
The CE of the test strategy improved as the rate of mastec-
tomy among BRCA-positive women increased across a range of
probabilities of mutation and dominated above an 80% rate of
mastectomy. The rates of oophorectomy among BRCA-positive
women also improved the CE of the test strategy until about
60%. Above this, the incremental beneﬁts decreased faster than
the incremental costs. For both prophylactic surgeries, the ICER
remained below $20k/QALY for the full range.
The results of the Monte Carlo simulation show that the test
strategy cost more (P < 0.001), but the effects were not signiﬁ-
cantly different (P = 0.42). The ICER was not signiﬁcantly
different from zero (P = 0.67). Figure 3 shows that all of the
conﬁdence ellipses crossed the origin. The test strategy domi-
nated for 11% of the results and was dominated by the no-test
strategy for 24%. The probability of the test strategy being
cost-effective or dominate was 73% when a QALY was valued at
$100k and 70% at $50k. Figure 4 shows the acceptability curve
based on the Monte Carlo simulation.
Discussion
Our results indicate that despite the costs associated with testing
and prophylactic procedures, testing women who are concerned
Table 5 Cumulative costs, QALYs, cancer incidence, and age of median survival for each arm of the model
Frequency
(%)
Cumulative
costs ($1000)
Cumulative
QALYs
Breast cancer
incidence (%)
Ovarian cancer
incidence (%)
Age of median
survival (years)
No-test strategy
Mutation 10 153 20.9 61 20 77
No mutation 90 113 22.9 4.9 1.3 85
Test Strategy
Positive result
Mutation
Mastectomy 2.5 132 20.5 0.9 30 81
Oophorectomy 1.5 143 20.0 45 0.9 81
No prophylactic surgery (but option to have it later) 5.9 151 20.6 58 15 78
No mutation
Mastectomy 0.17 117 22.0 0.5 1.3 85
Oophorectomy 0.10 115 20.7 2.8 0.1 85
No prophylactic surgery (but option to have it later) 0.41 114 22.3 4.0 0.8 85
Negative result
Mutation 0.09 156 21.0 61 20 77
No mutation 89 115 23.1 4.9 1.3 84
QALY, quality-adjusted life year.
Table 6 ICER ($1000/QALY) for various values of probability of mutation and utility gain from learning of negative test result
Probability of mutation
0% 5% 10% 15% 20%
Utility gain from learning of
negative test results
0
0.002 No-test strategy dominates
0.004 72.9 13,219.2
0.006 25.4 30.7 49.2
0.008 15.4 15.4 15.4 15.4 15.6
0.010 11.0 10.3 9.1 7.3 3.8
0.012 8.6 7.7 6.5 4.8 2.1
0.014 7.0 6.2 5.0 3.5 1.5
0.016 6.0 5.1 4.1 2.8 1.1
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
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about developing breast and ovarian cancers is economically
advantageous because it allows women at high risk for these
diseases to have a prophylactic surgery and avoid high costs,
morbidity, and mortality associated with having these cancers.
According to this model, the costs and beneﬁts for each strategy
are very similar when considered over the entire lifespan. This
implies that the costs of testing and prophylactic surgery are
approximately equivalent to the increased costs associated with
the higher incidence of cancers in the no-test strategy. Also, the
decrease in QALYs from knowledge of a mutation and prophy-
lactic surgery are approximately equivalent to the decrease in
QALYs from ovarian or breast cancer that was not prevented.
This study does not contradict the current guideline of testing
for women with greater than 10% pretest probability of muta-
tion. This implies that, in terms of CE and total costs, it is
appropriate for insurance companies to cover this service, even
using a conservative willingness-to-pay value of $50k/QALY. The
test strategy is cost-effective even when the probability of muta-
tion is 0, if a negative test result improves the woman’s quality of
life by at least 0.006. This suggests that it may be appropriate to
offer testing to those with a lower probability of mutation, as
long as there is some concern expressed by the woman. This
result is similar to the previous study ﬁnding that testing indi-
viduals of Ashkanazi Jewish descent, with a known prevalence of
mutation of 2.5%, is cost-effective when followed by prophylac-
tic surgery [18].
The probability of mutation at which the testing strategy is
cost-effective is dependent on the utility gain from receiving a
negative test result. This implies that it may be appropriate for
a woman who is very concerned, but has a low probability of
having the mutation, to have the test. If an individual patient is
near the cutoff for genetic testing, her speciﬁc preferences and
likely response to the information should factor into the decision
of whether she should be tested. Those for whom prophylactic
surgery is likely to be obtained with acceptable results will beneﬁt
more from the test than those for whom the surgery is not
currently an option. A copayment or similar measure may be
appropriate to discourage women from expressing greater
concern than they are actually experiencing to qualify for test
coverage. This should address any concern regarding moral
hazard. Genetic counseling, which is recommended before
testing, may also serve to ameliorate the concern of some women
who are at low risk.
The utility after BRCA mutation diagnosis in the ﬁrst year
was the parameter that was found to have the greatest impact on
the CE estimates in sensitivity analysis. Nevertheless, this was
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due to a rapid increase at the high and low ends of the range
(above 0.98 and below 0.1). Given the current knowledge about
BRCA testing and quality of life, it is unlikely that the true values
at these extreme ends of the scale.
There was an unexpected ﬁnding that increasing probability
of mutation decreased the CE of the test strategy. One would
expect that the more likely a person is to have the mutation, the
more effective the test would be. Nevertheless, this trend is only
present until the utility increase of learning of a negative test
result is below 0.01. This implies that the utility increase because
of the relief of not having the mutation for the majority of cases
needs to be above this threshold to counteract the loss of utility
among those who are found to have the mutation.
The model was also sensitive to how inconclusive test results
are interpreted, with the two methods used testing the extreme
possibilities. Although the no-test strategy dominates when
inconclusive results are treated as either of the two extreme cases
tested, the actual change in costs and beneﬁts is very small
compared to the base case. Currently, inconclusive results are
treated based on the pretest information, because the test result is
not helpful in revising the estimated probability of carrying the
mutation. In this situation, clinical judgment may be able to place
women into either the true positive or true negative categories. In
reality, any woman with signiﬁcant family history and an incon-
clusive result would receive, at a minimum, high level surveil-
lance and may be counseled to consider surgery. Inconclusive
results were not included in the primary model, because of the
lack of data regarding the likelihood of mutation and surgery in
these cases. Nevertheless, by evaluating the extreme scenarios,
we can get an estimate of how results would change. The differ-
ence in results between extreme scenarios was not substantial.
The impact of inconclusive results on CE highlights the impor-
tance of understanding the implications of different genetic muta-
tions and how results of genetic testing are handled in clinical
practice. Continued study of family breast and ovarian cancer
clusters can improve our understanding of which mutations are
clinically important, which in turn improves the CE of testing and
patient outcomes. Following upwith those who have inconclusive
results to understand how this affects their likelihood for surgery
and their quality of life would be valuable for future studies.
Based on the model results by arm, as shown in Table 5, there
is an advantage to those without the mutation to be tested (23.1
QALYs compared to 22.9), but a disadvantage to those with the
mutation (20.5 vs. 20.9). Although there is a slight survival
advantage for those with the mutation (79 years median survival
vs. 77), this is overshadowed by the decrease in utility because of
knowledge of the mutation and prophylactic surgeries. The rela-
tionship between these utility losses and how they change over
time is not known and they were not found to have a substantial
impact on the ICER estimated by this model, but they do impact
whether or not a woman with a mutation is predicted to beneﬁt
from this test. When these utilities were modeled with an expo-
nential function to return to the healthy age-speciﬁc quality of
life, instead of the base case linear function, this disadvantage
disappeared and became a slight advantage (20.859 vs. 20.851).
In addition to the utility losses for prophylactic surgeries and
knowledge of the mutation, the utility loss before testing is a key
parameter. When a woman does not know if she has the muta-
tion, but is at high risk, she has a slight decrease in utility because
of this uncertainty. No estimate exists in the literature for the
utility loss from this uncertainty, so a conservative value of 0.01
was used in this model. When a woman learns that she carries the
gene, she has a much greater loss in utility from this knowledge
and the implications this has on her life and on her female
relatives. One study [55] found that 14% of high-risk women
agreed with the statement “Knowing that I carry the gene would
worsen my quality of life” [55, p. 547] and 18% of the women
in this study stated that they did not intend to be tested. Further
investigation on these key utilities and how they vary over time is
necessary for more accurate models.
Although there are sophisticated computer models to predict a
woman’s probability of mutation, the predictors that have the
greatest impact are those that deﬁne who are eligible for insurance
coverage for testing. These criteria vary substantially and do not
appear to directly align with criteria suggested in the literature
[2,11–17,56]. These criteria tend to focus on past histories of ﬁrst
and second degree relatives, but vary on the number and types of
cancers and ages of onset required to be “at risk.” One set
of criteria was found to have a speciﬁcity of 37% and a sensitivity
of 81% [2]. This shows that testing may not currently be available
to a substantial number of women who could beneﬁt, including
some who are above the 10% probability of mutation currently
accepted as the cutoff for testing. Our results showing CE at low
mutation probabilities suggest that coverage restrictions based on
family history may not be necessary from a CE perspective.
Recent studies have found that breast magnetic resonance
imaging (MRI) is an effective means of surveillance for high-risk
women [57] and the American Cancer Society now recommends
MRI for women with a 20% to 25% lifetime risk of developing
breast cancer (based on either a strong family history of breast or
ovarian cancer or prior radiation therapy for Hodgkin’s lym-
phoma), those with a BRCA mutation, or those with unknown
mutation status who have a ﬁrst degree relative with a BRCA
mutation [45]. The use of MRI will increase the costs for sur-
veillance, but may also decrease treatment costs and increase
survival if cancers are detected in earlier stages. Once data
become available for the costs and outcomes of this new tech-
nique, CE analyses should be updated.
The utilities of living with breast cancer, ovarian cancer, mas-
tectomy, and oophorectomy were taken from studies published
between 1999 and 2005. The treatments and prognosis of cancer
diagnoses have changed over time, which may lead to different,
and likely higher, utility estimates. It is unclear if the information
given to the subjects included preventive action possibilities, such
as oophorectomy, that could lessen the impact of knowledge of
the mutation. With the current knowledge of the signiﬁcantly
reduced risk of cancer after surgery, it is possible that patients,
post-surgery, would not have signiﬁcant concern about the muta-
tion. Nevertheless, because cancer treatments themselves have
also changed over time, it is not possible to predict how the
overall results of this model would be affected. Additional data
on the quality of life experienced by women with BRCA muta-
tion test results, both negative and positive, would improve
future analyses.
Conclusion
The costs and effects for both the test strategy and the no-test
strategy are very similar and are not sensitive to parameter esti-
mates. Genetic testing for BRCA1/2 is a cost-effective strategy
regardless of pretest probability of mutation, as long as ﬁnding
out that she does not have a BRCA1/2 mutation improves a
woman’s utility by at least 0.006. These results suggest that it is
appropriate for insurance plans to cover BRCA1/2 testing, even
for women with a relatively low pretest probability of mutation.
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